Your browser doesn't support javascript.
loading
Adult-onset severe paroxysmal cold hemoglobinuria after COVID-19 successfully treated with sutimlimab.
Sato, Keijiro; Nakamura, Yusuke; Hara, Ryosuke; Kayama, Ryuhei; Sunohara, Shunya; Okajima, Sayaka; Kazama, Shintaro; Komaba, Wataru; Ishikawa, Ryuto; Sumi, Masahiko; Kobayashi, Hikaru.
Afiliación
  • Sato K; Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano City, Nagano, 380-8582, Japan. k.ssto.shv@gmail.com.
  • Nakamura Y; Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano City, Nagano, 380-8582, Japan.
  • Hara R; Department of Rheumatology, Minami Nagano Medical Center, Shinonoi General Hospital, Nagano, Japan.
  • Kayama R; Department of Rheumatology, Minami Nagano Medical Center, Shinonoi General Hospital, Nagano, Japan.
  • Sunohara S; Department of Clinical Laboratory, Nagano Red Cross Hospital, Nagano, Japan.
  • Okajima S; Laboratory Department, 1st Laboratory Division, Kanto-Koshinetsu Block Blood Center, Japanese Red Cross Society, Tokyo, Japan.
  • Kazama S; Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano City, Nagano, 380-8582, Japan.
  • Komaba W; Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano City, Nagano, 380-8582, Japan.
  • Ishikawa R; Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano City, Nagano, 380-8582, Japan.
  • Sumi M; Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano City, Nagano, 380-8582, Japan.
  • Kobayashi H; Department of Hematology, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano City, Nagano, 380-8582, Japan.
Int J Hematol ; 2024 Sep 20.
Article en En | MEDLINE | ID: mdl-39304597
ABSTRACT
Paroxysmal cold hemoglobinuria (PCH) is a form of cold autoimmune hemolytic anemia characterized by the presence of the Donath-Landsteiner antibody, which triggers complement-mediated intravascular hemolysis when the body temperature changes from cold to warm. PCH occurs primarily in children as a rare, self-limiting disease following viral infections. In contrast, adult-onset PCH is very rare and associated with a diverse range of underlying conditions, which complicates its management and treatment. We describe a case of adult-onset PCH following COVID-19, effectively managed with a single dose of sutimlimab, a selective classical complement pathway inhibitor. This intervention was performed during a life-threatening hemolytic crisis, at a time requiring swift decision-making when specific tests to differentiate from other hemolytic anemias were not readily available. This case illustrates the potential of using a single dose of sutimlimab to manage life-threatening hemolytic crises in PCH, highlighting the significance of inhibiting the classical complement pathway.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón